Cancer Design, synthesis and discovery of asciminib SAR-based BCR-ABL targeted proteosome degrader SIAIS-100 Jan. 13, 2023 The chromosomal translocation [t(9;22)] associated oncogenic fusion protein BCR-ABL drives 90% of chronic myelogenous leukemia (CML).Read More
